Beam Therapeutics

Valuation Analysis

About the Company

Beam Therapeutics en bref

Beam Therapeutics (BEAM) is currently trading at 29,79 € with a market capitalization of 3,1 Md €. The 52-week range spans from 13,61 € to 31,80 €; the current price is 6.3% below the yearly high. Year-over-year revenue growth stands at +324.9%.

💰 Dividende

Beam Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Beam Therapeutics (BEAM) au consensus : Achat Fort. L'objectif de cours moyen est de 44,57 €, soit un potentiel de +49.58% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 22,69 € à 69,81 €.

Beam Therapeutics : la thèse d'investissement en détail

Beam Therapeutics (BEAM) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 324.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 49.58% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.2, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 32.31% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 49.58% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (32.31%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Beam Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.